Management of Past EBV Infection

Interpretation of Serological Results and Management Approach

No specific treatment is recommended for patients with a past EBV infection who are asymptomatic, as indicated by the serological profile showing positive VCA IgG and EBNA IgG with negative VCA IgM, according to the American College of Physicians 1, 2
Monitoring is not routinely recommended for immunocompetent individuals with past EBV infection, as stated by the European Hematology Association 3
Antiviral medications have not shown efficacy against latent EBV and are not recommended for past EBV infections, as indicated by the European Hematology Association 4

In immunocompromised patients, regular monitoring of EBV DNA-emia may be warranted, according to the European Hematology Association 5, 3
For transplant recipients at high risk for EBV-related complications, prospective monitoring of EBV DNA levels is recommended for at least 4 months post-transplant, as stated by the European Hematology Association 3
Preemptive therapy with rituximab is only indicated for significant EBV DNA-emia without clinical symptoms in high-risk patients, according to the American College of Physicians and the European Hematology Association 4, 1

If EBV-related complications develop, rituximab is the first-line treatment, as recommended by the American College of Physicians 1, 2
For chronic active EBV infection, hematopoietic stem cell transplantation may be the only curative option, according to the American Society of Hematology 6, 2
Reduction of immunosuppression, when applicable, should be combined with rituximab therapy for EBV-related complications, as stated by the European Hematology Association and the American College of Physicians 4, 2

Do not confuse past infection with chronic active EBV infection, which requires persistent symptoms for >3 months, as indicated by the American Society of Hematology and the American College of Physicians 6, 2
Avoid unnecessary antiviral therapy for past EBV infection, as these medications are ineffective against latent EBV, according to the European Hematology Association 4
In immunocompetent individuals with past EBV infection, routine monitoring of EBV DNA levels is not recommended and may lead to unnecessary interventions, as stated by the European Hematology Association 3

The European Society for Blood and Marrow Transplantation recommends rituximab 375 mg/m² once weekly (1-4 doses) until EBV DNA-emia negativity for the treatment of EBV-PTLD after a prior allogeneic stem cell transplant, with a reduction of immunosuppression when possible 7, 8
This approach achieves positive outcomes in approximately 70% of patients, according to the European Society for Blood and Marrow Transplantation 8

The European Society for Blood and Marrow Transplantation recommends prospective monitoring of EBV DNA-emia by quantitative PCR for at least 4 months post-transplant in high-risk patients, with preemptive rituximab therapy indicated for significant EBV DNA-emia without clinical symptoms 7, 8, 9
Prophylactic EBV-specific CTLs should be considered as first-line prophylaxis when available, according to the European Society for Blood and Marrow Transplantation 7, 8

The European Society for Blood and Marrow Transplantation advises against prescribing antivirals (acyclovir, etc.) for EBV, as they are completely ineffective against latent or active EBV 7, 8
Reduction of immunosuppression alone is rarely successful and increases GvHD risk for EBV-PTLD after transplant, according to the European Society for Blood and Marrow Transplantation 7, 8